United States-based Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) has named Robert J Hugin as its new director effective immediately, it was reported on Wednesday.
Hugin earlier served as the chairman and chief executive officer of Celgene Corporation. He joined Celgene as chief financial officer in 1999 and served in various positions including executive chairman, chief executive officer, president and chief operating officer. He also held the position of director of Chubb Limited, member of the Board of Trustees of Princeton University and chair of The Darden School Foundation, University of Virginia. Presently, he is the chair of the board of the Garden State Initiative and a longstanding member of the board of Trustees of Family Promise. He is past chairman of the boards of The Pharmaceutical Research and Manufacturers of America and the Healthcare Institute of NJ. He has also served as managing director with JP Morgan and Company Limited.
Declan Doogan, MD, chairman of Biohaven's board of irectors, said, 'We are excited to welcome Bob to Biohaven's board of directors as we have evolved to a commercial organization and look to the future. Having access to Bob's astute business and financial acumen will help Biohaven achieve our goal of becoming the leading pharmaceutical company focused on neuroscience indications.'
Novo Nordisk expands legal action over compounded 'semaglutide'
Neuraxpharm launches Neuraxpharm Australia
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Fridays nominated for World Out of Home awards for weight loss campaign
Physiomics expands into biometrics with two contract wins and new division head
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
WuXi Biologics honoured for water security by CDP
Clario acquires imaging provider NeuroRx
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services